Effects of dronedarone, amiodarone and their active metabolites on sequential metabolism of arachidonic acid to epoxyeicosatrienoic and dihydroxyeicosatrienoic acids

Biochem Pharmacol. 2017 Dec 15:146:188-198. doi: 10.1016/j.bcp.2017.09.012. Epub 2017 Sep 25.

Abstract

Cardiac enzymes such as cytochrome P450 2J2 (CYP2J2) metabolize arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acids (EETs), which in turn are metabolized by soluble epoxide hydrolase (sEH) to dihydroxyeicosatrienoic acids (DHETs). As EETs and less potent DHETs exhibit cardioprotective and vasoprotective functions, optimum levels of cardiac EETs are paramount in cardiac homeostasis. Previously, we demonstrated that dronedarone, amiodarone and their main metabolites, namely N-desbutyldronedarone (NDBD) and N-desethylamiodarone (NDEA), potently inhibit human cardiac CYP2J2-mediated astemizole metabolism in vitro. In this study, we investigated the inhibition of recombinant human CYP450 enzymes (rhCYP2J2, rhCYP2C8, rhCYP2C9)-mediated AA metabolism and human recombinant sEH (rhsEH)-mediated EET metabolism by dronedarone, amiodarone, NDBD and NDEA. A static model describing sequential metabolism was further developed to predict the aggregate effect of dual-inhibition of rhCYP2J2 and rhsEH on the fold-of 14,15-EET level (CEET'/CEET). Dronedarone, amiodarone and NDBD inhibit rhCYP2J2-mediated metabolism of AA to 14,15-EET with Ki values of 3.25, 5.48, 1.39µM respectively. Additionally, dronedarone, amiodarone, NDBD and NDEA inhibit rhsEH-mediated metabolism of 14,15-EET to 14,15-DHET with Ki values of 5.10, 13.08, 2.04, 1.88µM respectively. Based on static sequential metabolism modelling, dronedarone (CEET'/CEET=0.85), amiodarone (CEET'/CEET=0.48) and NDBD (CEET'/CEET=0.76) were predicted to decrease cardiac 14,15-EET level whereas NDEA (CEET'/CEET>35.5) was predicted to elevate it. Based on our novel findings, we postulate the differential cardiac exacerbation potential of dronedarone and amiodarone is partly associated with their differential inhibition potencies of cardiac CYP2J2 and sEH.

Keywords: 14,15-Dihydroxyeicosatrienoic acid (PubChem CID: 5283147); 14,15-Epoxyeicosatrienoic acid (PubChem CID: 5283205); AUDA (PubChem CID: 10069117); Amiodarone; Amiodarone (PubChem CID: 2157); Amiodarone hydrochloride (PubChem CID: 441325); Arachidonic acid (PubChem CID: 444899); CYP2J2; Danazol (PubChem CID: 28417); Dronedarone; Dronedarone (PubChem CID: 208898); Dronedarone hydrochloride (PubChem CID: 219025); Epoxy fluor 7 (PubChem CID: 25093347); Epoxyeicosatrienoic acids; N-desbutyldronedarone (PubChem CID: 10255437); N-desethylamiodarone (PubChem CID: 104774); Soluble epoxide hydrolase.

MeSH terms

  • 8,11,14-Eicosatrienoic Acid / analogs & derivatives
  • 8,11,14-Eicosatrienoic Acid / chemistry
  • 8,11,14-Eicosatrienoic Acid / metabolism
  • Amiodarone / analogs & derivatives*
  • Amiodarone / chemistry
  • Amiodarone / metabolism
  • Amiodarone / pharmacology*
  • Arachidonic Acid / metabolism*
  • Cytochrome P-450 CYP2J2
  • Cytochrome P-450 Enzyme Inhibitors / chemistry
  • Cytochrome P-450 Enzyme Inhibitors / metabolism
  • Cytochrome P-450 Enzyme Inhibitors / pharmacology
  • Cytochrome P-450 Enzyme System / metabolism
  • Dronedarone
  • Humans
  • Kinetics

Substances

  • 14,15-dihydroxyeicosatrienoic acid
  • CYP2J2 protein, human
  • Cytochrome P-450 Enzyme Inhibitors
  • N-desbutyldronedarone
  • Arachidonic Acid
  • 14,15-epoxy-5,8,11-eicosatrienoic acid
  • Cytochrome P-450 Enzyme System
  • Cytochrome P-450 CYP2J2
  • 8,11,14-Eicosatrienoic Acid
  • Dronedarone
  • desethylamiodarone
  • Amiodarone